Neurocrine Biosciences, Inc. (NBIX) Q1 2016 Earnings Results

Neurocrine Biosciences Beats on EPS, Stock Down 0.61%

Neurocrine Biosciences reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock dipped slightly by 0.61%, possibly due to a lack of revenue information and no updated guidance. Investors may be weighing the positive EPS surprise against uncertainty in revenue and future projections.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.22	N/A	+20.58%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management remains cautiously optimistic about future developments. They emphasized their focus on advancing their product pipeline.

Management expressed confidence in their ongoing projects and pipeline.

They highlighted the importance of upcoming clinical trials.

Neurocrine Biosciences Beats on EPS, Stock Down 0.61%

Key numbers

Management commentary

Neurocrine Biosciences, Inc.

More earnings this week

Neurocrine Biosciences Beats on EPS, Stock Down 0.61%

Key numbers

Management commentary